Last update 8 February 2016
AUTHOR QUERIES FOR COPY-EDITORS
 Use these as far as possible for your queries, but you may need to adapt them to suit the
particular paper and to make them more specific. It’s especially useful to provide specific
examples of the styling of genes or proteins mentioned in the paper.
 Please make you queries as succinct and specific as possible to reduce the number/length
of queries.
Ctrl + click on any of the following topics to take you straight to the query:
TITLE
Modification of title (general)
Modification of title (animal)
AFFILIATIONS
Author names
Affiliation
Affiliations (order)
Two corresponding authors
Study Group
Study Group on PubMed
CIBERDEM and CIBERESP
Singapore in affiliations
China in affiliations
Hong Kong in affiliations
Particles
ABBREVIATIONS
Abbreviations (standard)
Abbreviations (written-out)
Abbreviations (gene symbols)
THROUGHOUT TEXT
Subjects vs participants
Caucasians
Triglyceride/triacylglycerol
Free fatty acids/NEFA
HDL/LDL
Gender/Sex
Male/Female
Latin terms
Wt or vol.
High-/low-calorie and isocaloric
Parameters/variables
Websites
Antidiabetic drugs
Prediabetes
Utilise
Optical density
ETHICS PERMISSION
Ethics permission (animals)
Ethics permission (humans)
Ethics permission (organ donors)
Ethics permission (donated human
cells
Ethics permission (database studies)
BRIEF ADDRESSES FOR SOURCES
Address (animals)
Address (chemicals/equipment)
UNITS
SI units
Dual reporting of HbA1c units
Units for area under the curve (AUC)
HOMA equation
MINMOD program (insulin
sensitivity)
Molecular weight/mass
Normal (N) values for solutions
Units (U)/International Units (IU)
PRECLINICAL STUDIES
Replicates
Data expression
Statistics
Randomisation
Blinding
Exclusion
Animal strain
Antibodies
GENES/PROTEINS
Styling: genes vs proteins
Styling: human vs rat/mouse
Styling: mRNA
Styling: western blots
Styling: northern blots
Styling: knockdown studies
Expressed vs produced (general)
Expressed vs produced (cell surface
markers)
Expressed vs produced (mRNA)
Old vs up-to-date symbol (human)
Keywords: Add old and up-to-date
symbols
HLA allele format
HLA gene family styling
Gene set analyses
PCR primers
STATISTICS
Statistics: r values
Data expression
Statistical tests
RANDOMISED CONTROLLED
TRIALS
CONSORT guidelines: abstract
CONSORT guidelines: flow diagram
Trials mentioned in other types of
article
MISCELLANEOUS
Unpublished observations/results/data
Personal communication
Animal models of diabetes
Logarithms
Logarithms (ln)
ICD-9 and -10
Drug names
Insulin analogues
Sacrificed vs killed
Abstracts in commentaries
qRT-PCR
ACKNOWLEDGEMENTS,
AUTHOR CONTRIBUTION
STATEMENT AND DUALITY OF
INTEREST
Acknowledgements
Funding
Funding by UK research councils
Funding by the Wellcome Trust
Contribution statement
Guarantor
Duality of interest
Data in repositories
REFERENCES
Author name/reference mismatch
Abstract out-of-date
Reference in preparation/submitted
In press
Accepted for publication
ePub ahead of print
Websites
Cochrane reviews
FIGURES
Figure part labelling
Deletion of legend
Deletion of p values
Figures not cited in rising order
Explanation of statistical symbols
Change of statistical symbols
p values
High-resolution figures
Forest plots
Scale bars
TABLES
Tables not cited in rising order
Formatting (gridlines)
Formatting (rows of space)
Formatting (bold type)
Formatting changes
ESM
COMMENTS (LETTERS)
Comment title
Reply to comment, title
Page 2 of 40
TITLE
Modification of title (general)
The title has been modified slightly in line with journal style [details].
Modification of title (animal)
The animal species has been added to the title in line with journal policy.
<Back to index>
Page 3 of 40
AFFILIATIONS
Author names
Diabetologia style is to include given (first) name, initials and family name in the author list,
e.g. Gregory M. Bunke, Yu-fei Shan, Soo Heon Kim, J. Edgar Hoover. Please ask your coauthors to amend their names in line with this, as appropriate.
[Copyeditors and proofreaders please note that Korean given names are often unhyphenated
two-part names such as Soo Heon, Sung Hee, and in this case both names should be retained
in the author list. Please check with the Editorial Office or raise an author query if you are
unsure.]
Affiliation
In line with journal style, affiliation XXX has been replaced with the address for
correspondence.
Please check that this address applies to all authors listed as having this affiliation and modify
if necessary.
OR
In line with journal style, affiliation XXX has been amended to include the full address for
correspondence.
Please check that this address applies to all authors listed as having this affiliation and modify
if necessary.
Affiliation (more than one)
Different affiliations, including different departments within the same institution (but not
joint departments) should be listed separately.
Should affiliation [?] therefore be rewritten as …?
Affiliation (postal details)
Full postal details are only needed for the address of the corresponding author, and have been
deleted from other affiliations.
Affiliations (order)
The publisher requires that affiliations should be given in the order: department, institution,
town/city, country. Please amend affiliation XXX in line with this.
Affiliations (ask co-authors to check all affiliations have been included)
Please check with your co-authors that they have included all their affiliations, as it is
difficult to add additional affiliations at the proof stage.
Page 4 of 40
Affiliations (corporate affiliation moved from footnotes/acknowledgements)
In order to include full affiliation details for each author, we do not include affiliation details
as footnotes or acknowledgements. Therefore the details of (COMPANY NAME) have been
added as an additional affiliation. Please check with your co-author that this is acceptable.
Please note that this change might need to be checked and approved by the compliance team
of the company in question; let us know if this change contravenes compliance guidelines.
Two corresponding authors
Which of the two corresponding authors would you like to nominate to receive proofs?
Study Group
Please check with your co-authors and/or trial co-ordinators to ensure that any guidelines for
the representation of the Study Group in the title, author list and affiliations are followed.
Confirm that you mean ‘on behalf of’ rather than ‘and’.
Confirm that you mean ‘and’ rather than ‘on behalf of’.
Study Group members on PubMed
You include XXX Study Group in the author list and in the
footnotes/acknowledgements/appendix/ESM you have identified people as authors or as
members of the writing group/writing committee for this study group. They will therefore be
added as authors on MEDLINE/PubMed (and will be appear after any authors listed in the
main author list on the paper).
For more information, see the NLM Fact Sheet Authorship in MEDLINE at
www.nlm.nih.gov/pubs/factsheets/authorship.html.
Please include full affiliation details of study group authors/members of the writing group,
with details of department, institution, city, state (USA, Canada and Australia) and country.
CIBERDEM and CIBERESP
The organisation CIBERDEM is not usually given with a town/city. Please confirm that we
can insert the URL instead, e.g.
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas
Asociadas (CIBERDEM), Spain
URL www.ciberdem.org/
The organisation CIBERESP is not usually given with a town/city. Please confirm that we
can insert the URL instead, e.g.
Page 5 of 40
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP),
Spain
URL www.ciberesp.es/
Singapore in affiliations
We are required to provide both city and country for affiliations. ‘Republic of Singapore’ has
therefore been inserted after ‘Singapore’.
China in affiliations
Can ‘China’ be replaced by ‘People’s Republic of China’?
Hong Kong in affiliations
Can ‘Hong Kong’ be replaced by ‘Hong Kong Special Administrative Region’?
Particles in author names (de, de la, von, van, del, etc.)
Author name: XXX
It is important that you check with your co-author exactly how they would like their name to
appear in the author list (this will determine how it appears in PubMed).
[Insert specific example]
For example:
Jane von Braun: appear as ‘von Braun, J, ‘Von Braun, J’ or ‘Braun, JV’ or ‘Braun, J’?
In particular, please confirm lower or uppercase for von/Von.
<Back to index>
Page 6 of 40
ABBREVIATIONS
Abbreviations (standard)
XXX is a standard abbreviation (see www.diabetologiajournal.org/webpages/abbreviations.html) that can be used without definition. Your paper has
been amended accordingly
If used more than once, the abbreviation has been added to the abbreviations list.
Please note that abbreviations used only once in the paper will not be included in the
abbreviations list.
Abbreviations (written-out)
Please give written-out versions of:
XXX
Abbreviations (gene symbols)
Gene symbols are not true abbreviations and so have been deleted from the abbreviations list.
[List here]
<Back to index>
Page 7 of 40
THROUGHOUT TEXT
Subjects vs participants
To make it clear to readers that participation in the study was voluntary, Diabetologia prefers
that ‘subject’ is replaced by another term such as ‘participant’, ‘individual’ or ‘volunteer’.
This change has been made for you throughout. (An exception is made for people who are
studied by use of a database where permission is not sought from each individual.)
Caucasians
In line with AMA recommendations (AMA Manual of Style, 10th edn, ch 11.10.2
Race/Ethnicity, p. 415), Diabetologia does not use the term ‘Caucasian’, which is considered
to be non-specific and inaccurate. The term ‘white’ is a suitable alternative: this change has
been made for you throughout (‘Europid’ or ‘of European descent’ are also acceptable terms).
Triglyceride/triacylglycerol
In line with IUPAC recommendations
(http://www.iupac.org/publications/books/principles/principles_of_nomenclature.pdf, p. 129),
‘triglyceride’ has been changed to ‘triacylglycerol’ throughout the paper.
[Note that the exception to this is the enzyme ‘adipose triglyceride lipase’, which should not
be changed to ‘adipose triacylglycerol lipase’.]
<Back to index>
Free fatty acids/NEFA
In line with IUPAC recommendations
(http://www.iupac.org/publications/books/principles/principles_of_nomenclature.pdf), ‘free
fatty acid’ has been replaced by ‘NEFA’ (non-esterified fatty acid)
HDL/LDL
Where you use the terms ‘HDL’ and ‘LDL’ are you referring to HDL-cholesterol and LDLcholesterol, respectively? Please change where appropriate.
Gender/sex
‘Gender’ (cultural term) has been replace by ‘sex’ (biological term) throughout.
Page 8 of 40
Males/females
Males/females used as nouns have been replaced with men/women (male/female are
generally used as adjectives when referring to people).
Latin terms
In line with journal style, Latin terms that appear in the Oxford English Dictionary, e.g. in
vitro, will be formatted in upright type, not italics.
<Back to index>
Wt or vol.
Please specify whether % concentrations are by weight or by volume (e.g. wt/vol., wt/wt,
etc.):
[e.g. Provide a single example here]
High-/low-calorie and isocaloric
‘High-calorie’ has been replaced by ‘high-energy’ throughout (calorie is a unit rather than an
adjective).
‘Low-calorie’ has been replaced by ‘low-energy’ throughout (calorie is a unit rather than an
adjective).
[Note that the term VLCD, very low calorie diet, is allowed because it is widely used in the
literature. It should be described as a ‘diet very low in energy (very low calorie diet
[VLCD])’ at first mention]
‘Isocaloric’ has been replaced by ‘isoenergetic’ throughout (calorie is a unit rather than an
adjective).
Parameters/variables
‘Parameter’ is used for an arbitrary constant within an experiment or mathematical term,
whereas ‘variable’ is used for an expression that can be assigned any of a set of values. In
line with this standard English usage, parameters has been replaced by variables where
appropriate.
Websites
Please give the date that the site was accessed (day/month/year).
Page 9 of 40
Antidiabetic drugs
In line with journal policy, ‘antidiabetic’ drugs has been replaced by ‘glucose-lowering’
drugs. The term ‘hypoglycaemic’ drugs would also be acceptable if you prefer.
Page 10 of 40
Prediabetes: type 2
Diabetologia prefers to avoid the terms ‘prediabetes’ and ‘prediabetic’ except in a purely
temporal sense. As prediabetes does not have an accepted definition, please replace with, for
example, ‘impaired glucose tolerance’ and/or ‘impaired fasting glucose’.
Prediabetes: type 1
Diabetologia prefers to avoid the terms ‘prediabetes’ and ‘prediabetic’ except in a purely
temporal sense. As prediabetic does not have an accepted definition, please replace with, for
example, ‘at risk of diabetes’ or ‘with diabetes-related autoantibodies’.
Utilise
Strictly speaking, ‘utilise’ means to make the best use of something not intended for the job.
Instances of ‘utilise’ have been changed to ‘use’ throughout.
Optical density
The Oxford Dictionary of Biochemistry and Molecular Biology no longer recommends the
use of ‘optical density’ as an alternative for ‘absorbance’. Can OD450 and OD690 be changed
to absorbance at 450 and 690 nm respectively? [change these wavelengths as appropriate]
<Back to index>
Page 11 of 40
ETHICS PERMISSION
Ethics permission (animals)
Please insert a sentence confirming that experiments involving animals were approved by the
local ethics committee or that the study was conducted in accordance with the Guide for the
care and use of laboratory animals (2011) (http://grants.nih.gov/grants/olaw/guide-for-thecare-and-use-of-laboratory-animals.pdf)
Ethics permission (humans)
Please insert a sentence confirming: (1) that study participants gave informed consent; and
(2) that your investigations have been approved by the responsible ethics committee
(institutional review board) and/or were carried out in accordance with the Declaration of
Helsinki as revised in 2008 (www.wma.net/en/30publications/10policies/b3/index.html).
Ethics permission (organ donors/autopsy samples)
Organ donors: please insert a sentence confirming that your investigations have been
approved by the responsible ethics committee (institutional review board).
Autopsy samples: please insert a sentence confirming that your investigations have been
approved by the responsible ethics committee (institutional review board).
Donated human cells: please insert a sentence confirming that your investigations have been
approved by the responsible ethics committee (institutional review board).
Ethics permission (database studies)
Please insert a sentence confirming that the study has the approval of the local ethics
committee and/or health authority from which the data were obtained.
[Not needed for publically available gene databases such as MAGIC, DIAGRAM, GIANT,
GLGC, ICBP, ADIPOgen, or if the data are anonymised, i.e. individual patients cannot be
identified, but if in doubt, raise an AQ or ask the Editorial Office.]
<Back to index>
Page 12 of 40
BRIEF ADDRESSES FOR SOURCES
Address (animals)
Please give the source (supplier’s name, city, state [for USA, Canada, Australia] and
country), species, strain, international strain nomenclature, sex, genetic background and age
of animals as well as details of housing and husbandry.
[Provide examples here]
Address (chemicals/equipment)
Please give the name, city, state (for USA, Canada, Australia) and country for the following
manufacturers/suppliers on first mention.
[Provide examples here]
Address (software)
For software, the URL from which the software was downloaded can be given as an
alternative to the physical address.
[Please include the software version used].
<Back to index>
Page 13 of 40
UNITS
SI units
Diabetologia uses SI units throughout. For an SI conversion table see
AMA Manual of Style: SI Conversion Table
NB An exception is made for administered doses of insulin, which can be given in U.
Please convert values for XXX into SI units.
[give specific variables/units/location(s)]
Please convert values for plasma glucose to SI units (mmol/l).
Please convert values for plasma insulin to SI units (pmol/l).
Please convert units for radioactivity in Ci to SI units (Bq).
Please convert values for ACR in mg/g to SI units (mg/mmol).
Please convert values for centrifuge speed in rpm to g.
Please convert units for energy in kcal to SI units (kJ or MJ). If you wish, you may give
values in non-SI units (kcal) in parentheses. Please use the conversion factor 1 kcal = 4.184
kJ.
Please re-draw Fig. 000 to show XXX in SI units (XXX) and send it to us directly by email.
<Back to index>
Dual reporting for HbA1c units
In line with current recommendations, Diabetologia includes dual reporting of HbA1c units.
Please include values for HbA1c in percentage units with International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC) units (mmol/mol) in parentheses.
e.g. HbA1c level was 5% (31 mmol/mol)
For details of the conversion from NGSP (DCCT) percentage units (used in the UK, USA and
many other countries) to IFCC units, see http://www.ngsp.org/docs/IFCCstd.pdf. A
conversion calculator can be found at http://www.diabetes.co.uk/hba1c-units-converter.html
[If the study includes data from Sweden or Japan or is a review with data from a variety of
sources, please also add the following, and amend as necessary:]
Data from Sweden or Japan may contain HbA1c percentage units calculated in a slightly
different way. For details of conversion from Mono-S units (Sweden) or Japanese Diabetes
Society (JDS; Japan) see www.ngsp.org/docs/IFCCstd.pdf
Page 14 of 40
[For figures with values in NGSP (DCCT) percentage units, please add the following if
applicable]
Where you have included HbA1c values in % in Figure 000 the following has been added to
the figure legend:
To convert values for HbA1c in DCCT % into mmol/mol, subtract 2.15 and multiply by
10.929
Please confirm.
[For tables, please add the following]
Please include HbA1c values expressed in mmol/mol in a separate row below the % values.
Units for area under the curve (AUC)
The units for area under the curve (AUC) should be in the format y-axis unit × x-axis unit
(e.g. for glucose level vs time, the unit would be mmol/l × min). Please check your units to
ensure that they are correct.
<Back to index>
HOMA equation
We cannot accept the HOMA equation written-out with non-SI units. If you would like to
provide an equation, it should include SI units (glucose in mmol/l, insulin in pmol/l). Please
bear in mind that the constant will also be altered (note that the constant varies depending on
the standardisation of your insulin assay and its cross-reactivity with proinsulin species and
will be approximately 380–420).
Important: It is not necessary to recalculate the HOMA values, as equations with non-SI
units generate the same values as equations with SI units (which is why they have different
constants), provided that values in the units specified in the particular equation are used.
Alternatively, you may omit the equation and provide a reference. In this case, you may need
to re-number the subsequent citations in the text and in the reference list.
If you used the computer-generated HOMA2 index to calculate your results, you should refer
to this directly (e.g. www.dtu.ox.ac.uk) and include the date that you accessed the site (day,
month, year).
<Back to index>
Page 15 of 40
MINMOD program (insulin sensitivity)
To enable comparison of units for insulin sensitivity index generated by the MINMOD
program with results in other papers, we have included a conversion factor to SI units (i.e. to
convert values to SI units multiply by 0.167).
<Back to index>
Molecular weight/mass
Note that molecular weight is the former name for relative molecular mass (Mr), which has no
units. Molecular mass is given in kDa. Please check that you have used these terms correctly.
Normal values (N) for solutions
Please change normal (N) values for solutions to mmol/l.
[Give example]
Units (U)/International Units (I/U)
‘IU’ has been changed to the more commonly used ‘U’. Please let me know if the intended
meaning has been changed.
<Back to index>
Page 16 of 40
PRECLINICAL STUDIES (involving animals, cells or tissue)
Authors are encouraged to follow the NIH guidelines regarding reporting of experimental
conditions (http://www.nih.gov/about/reporting-preclinical-research.htm) to facilitate the
replication and interpretation of experiments. In line with this, please include the following
information in your article.
Statistics
Please include a sentence to state how your data were expressed e.g. ‘Data are expressed as
means (SEM)’
Please provide details of statistical tests used in your analysis.
Replicates
Please state how often each experiment was performed and whether the results were
substantiated by repetition under a range of conditions.
Randomisation
For animal experiments, please state whether the samples were randomised and specify the
method of randomisation.
Blinding
Please state whether experimenters were blind to group assignment and outcome assessment.
Inclusion and exclusion criteria
Please state criteria used for exclusion of any data, samples or animals. Include any similar
experimental results that were omitted from the reporting for any reason, particularly if the
results do not support the main findings of the study. Describe any outcomes or conditions
that were measured or used and are not reported in the results section.
Animal strain
Please give the source (supplier’s name, city, state [for USA, Canada, Australia] and
country), species, strain, international strain nomenclature, sex, genetic background and age
of animals as well as details of housing and husbandry.
Studies involving cell lines [Human or animal cell lines, not donor cells]
Please report the source, authentication and mycoplasma contamination status of cell lines
used.
Page 17 of 40
Antibodies
Please report source, characteristics and dilutions of antibodies and how they were validated.
<Back to index>
Page 18 of 40
GENES/PROTEINS
Styling: genes vs proteins, human vs mouse genes
Diabetologia distinguishes between gene symbols and protein abbreviations by using italic
font for gene symbols and upright font for protein abbreviations. Please note that gene
symbols for humans are styled in uppercase italics, whereas those for rats/mice are styled
with an initial capital letter and the remaining letters in lowercase italics. Please check your
paper carefully to ensure that you have made this distinction correctly.
For example:
Human gene: XYZ
Rat/mouse gene: Xyz
Protein (any species): XYZ
Styling: mRNA
mRNA and cDNA should be referred to in italic text using the correct gene symbol.
For example: Xyz mRNA
Styling: western blots
Since western blots are used to measure relative amounts of proteins, protein abbreviations
should be used. Please check that the correct styling (upright capitals) has been used
throughout.
<Back to index>
Styling: northern blots
Since northern blots are used to measure gene transcription/levels of mRNA, gene symbols
should be used. Please check that the correct styling has been used throughout.
<Back to index>
Styling: knockdown studies
Where siRNA or similar methods are used for knockdown studies, protein formatting should
be used for the molecule knocked down, whereas the oligonucleotide used for the knockdown
is formatted using the gene symbol. Please check your paper to ensure that this has been done
correctly.
For example ‘knockdown of ABC was carried out using Abc siRNA’
Page 19 of 40
Expression of proteins
For clarity, the term ‘expression’ has been replaced by ‘levels’ or ‘content’ in instances
where protein levels are being quantified, e.g. western blots.
<Back to index>
Unofficial vs official gene symbol
Diabetologia uses the Entrez Gene site (mouse, rat, human, etc.)
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene
to check gene symbols. Where you have used an unofficial symbol (alias) for the gene, the
up-to-date name has been added in parentheses at first mention in the abstract and in the text.
For example: Xyz (also known as Abc)
Keywords: Add unofficial and up-to-date symbols
To aid electronic scanning we have included both the unofficial gene symbol and up-to-date
symbol in the keywords (Xyz and Abc).
[Insert symbols for Xyz and Abc]
HLA allele format
Diabetologia uses the up-to-date formatting guidelines for HLA alleles, as detailed in
http://hla.alleles.org/nomenclature/naming.html. Please check that your manuscript complies
with this and make any necessary changes.
HLA gene family styling
HLA is not a gene, but a gene family. It is therefore not styled in italics but should be upright.
This change has been made for you throughout.
<Back to index>
Gene set analyses
GSEA software (www.broad.mit.edu/gsea). The following references should be cited in
addition to the website URL. Please re-number subsequent references in the text and
reference list as necessary.
Subramanian A, Tamayo P, Mootha VK et al. (2006) Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl
Acad Sci U S A 102:15545-15550.
Page 20 of 40
Mootha VK, Lindgren CM, Eriksson K-F et al. (2003) PGC-1α-responsive genes
involved in oxidative phosphorylation are coordinately downregulated in human
diabetes. Nat Genet 34:267-273.
SHEsis software (http://analysis.bio-x.cn/SHEsisMain.htm). The following reference should
be cited in addition to the website URL. Please re-number subsequent references in the text
and reference list as necessary.
Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage
disequilibrium, haplotype construction, and genetic association at polymorphism loci.
Cell Res 15:97–98
If the haplotype analysis function is cited, then the following reference should be cited in
addition to Shi & He:
Li Z, Zhang Z, He Z et al (2009) A partition-ligation-combination-subdivision EM
algorithm for haplotype inference with multiallelic markers: update of the SHEsis
(http://analysis.bio-x.cn). Cell Res 19:519–523
PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/). The following reference
should be cited in addition to the website URL. Please re-number subsequent references in
the text and reference list as necessary.
Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a toolset for whole-genome
association and population-based linkage analysis. Am J Hum Genet 81:559–575
Genetic Power Calculator software (http://ibgwww.colorado.edu/~pshaun/gpc/). The
following reference should be cited in addition to the website URL. Please re-number
subsequent references in the text and reference list as necessary.
Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and
association genetic mapping studies of complex traits. Bioinformatics 19:149–150
MeV (MultiExperiment Viewer) software (http://www.tm4.org/mev.html). The following
references should be cited in addition to the website URL. Please re-number subsequent
references in the text and reference list as necessary.
Saeed AJ, Bhagabati NK, Braisted JC et al (2006) TM4 microarray software suite.
Methods Enzymol 411:134–193
Saeed AJ, Sharov V, White J et al (2003) TM4: a free, open-source system for
microarray data management and analysis. Biotechniques 34:374–378
PCR primers
Please create a table of primers rather than listing them in the Methods, and allow us to
publish this as electronic supplementary material (ESM) on our website. Please insert a
reference to the electronic supplementary material at relevant places in the text and supply the
ESM table as a separate pdf document. Please ensure that the ESM files are cited in
numerical order in the text.
Page 21 of 40
<Back to index>
Page 22 of 40
STATISTICS
Statistics (r values)
Please check notation is used correctly:
r
bivariate correlation coefficient
R
multivariate correlation coefficient
Data expression
Please include a sentence to state how your data were expressed e.g. Data are expressed as
means (SEM)
Statistical tests
Please provide details of statistical tests used in your analysis.
<Back to index>
Page 23 of 40
RANDOMISED CONTROLLED TRIALS
CONSORT guidelines: abstract
Thank you for completing your CONSORT checklist for abstracts and for including this
information in your abstract (see www.consort-statement.org/?o=1001).
In line with these guidelines, please could you also add the following information to your
abstract:
OR
In line with CONSORT guidelines (http://www.consort-statement.org/?o=1001) on the
reporting of randomised controlled trials, please add the following information to your
abstract:
[Pick as appropriate]
Title
Include identification of the study as randomised.
Trial design
Include description of trial design (e.g. parallel, crossover, cluster).
Methods
Include eligibility criteria for participants and the setting where the data were collected
Include the interventions intended for each group.
Include specific objective or hypothesis.
Include a clearly defined primary outcome for this report.
Include a description of how participants were allocated to interventions and details of
allocation concealment, e.g. allocation by central office; sequentially numbered, opaque,
sealed envelopes.
State whether or not participants, caregivers, people doing measurements or examinations, or
people assessing the outcomes were blinded to group assignment. Avoid use of terms such as
‘single’- and ‘double’-blinded as these terms are not specific.
Results
Include the number of participants randomised to each group.
Include the number of participants analysed in each group.
For the primary outcome, include a result for each group and the estimated effect size and its
precision.
Include important adverse (or unexpected) effects or side effects.
Conclusions
Page 24 of 40
Include general interpretation of the results.
Trial registration
In line with ICMJE guidelines (www.icmje.org/urm_main.html), Diabetologia requires
authors to have registered clinical trials in a registry at the time of conception.
Acceptable registries include any registry that is a primary register of the WHO International
Clinical Trials Registry Platform (see www.who.int/ictrp/network/primary/en/index.html) or
in ClinicalTrials.gov (http://clinicaltrials.gov/)
Funding
Include the source of funding.
For examples of abstracts formatted in this way, see:
http://www.consortstatement.org/Media/Default/Downloads/Extensions/CONSORT%20Extension%20for%20A
bstracts%20Checklist.pdf
<Back to index>
CONSORT guidelines: flow diagram
In line with CONSORT guidelines (http://www.consort-statement.org/?o=1001) on the
reporting of randomised controlled trials, please include a flow diagram as one of the figures
showing Enrolment/Allocation/Follow-up/Analysis (for an outline flow diagram see
http://www.consortstatement.org/Media/Default/Downloads/CONSORT%202010%20Flow%20Diagram.doc).
<Back to index>
Trials mentioned in other types of article
The International Committee of Medical Journal Editors (ICMJE) recommends that the trial
registration number of clinical trials should be included at first mention of the trial in the
manuscript. Please include relevant trial numbers in the text in line with this.
<Back to index>
Page 25 of 40
MISCELLANEOUS
Unpublished observations/results/data
Please insert the names of the authors linked to the unpublished observations. For authors that
are not listed as authors of the present paper, we require written consent to cite their results.
Please email a copy of this confirmation directly to us. Alternatively, you may replace this
with a suitable reference (re-numbering subsequent references in the text and in the reference
list).
Personal communication
Please add an affiliation(s) for the communicant(s) (e.g. institute, city, country).
We require written consent to cite the communication if the communicant is not an author of
the present paper. Please email a copy of this confirmation directly to us.
<Back to index>
Animal models of diabetes
Note that animals are used as models of type 1 and 2 diabetes; they cannot have type 1 or
type 2 diabetes. In the title, and at first mention in the abstract and in the text, your wording
has been changed to indicate that the animals are used as a model of diabetes.
Logarithms
Please give details of the base used for logarithmic transformations (for example log10).
Logarithms (ln)
The format ‘ln’ may not be familiar to all readers. Can this be replaced by loge?
ICD-9 and ICD-10
Where you mention ICD-9, the website URL has been added:
(www.icd9data.com/2007/Volume1)
Where you mention ICD-10, the website URL has been added:
(www.who.int/classifications/icd/en/).
<Back to index>
Drug names
Page 26 of 40
European Law requires use of the Recommended International Non-proprietary Name (rINN)
for medicinal substances (http://www.pharmj.com/pdf/news/pj_20040313_bnf.pdf). In line
with this, the drug name XXX has been changed to YYY.
As glyburide is a US-named drug and may not be familiar to European readers, it has been
replaced by ‘… glibenclamide (known as glyburide in the USA and Canada) … ’
Adrenaline/noradrenaline
Adrenaline and noradrenaline are the official names used by EU members, so have been used
throughout, with epinephrine/norepinephrine added in parentheses at first mention.
Insulin analogues
The full name of the insulin analogue has been added at first mention:
insulin lispro (B28Lys,B29Pro human insulin)
insulin aspart (B28Asp human insulin)
insulin glargine (A21Gly,B31Arg,B32Arg human insulin)
insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin)
insulin glulisine (B3Lys,B29Glu human insulin)
insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin)
[Choose as appropriate]
Sacrified vs killed
In line with the dictionary definitions, ‘sacrificed’ has been changed to ‘killed’ (there was no
ritual involved). Another alternative would be ‘euthanised’.
Abstracts in commentaries
You may insert an unstructured abstract if you wish. Note that some readers only have access
to abstracts, not the full text, on PubMed.
qRT-PCR
RT-PCR is a standard abbreviation for ‘reverse transcription PCR’. Please either use the
abbreviation qPCR for quantitative real-time PCR or, if the PCR involves reverse
transcription, the abbreviation qRT-PCR can be retained but this should be made clear when
the abbreviation is first defined.
Page 27 of 40
<Back to index>
Page 28 of 40
ACKNOWLEDGEMENTS AND DUALITY OF INTEREST
Acknowledgements
[Delete as appropriate]
Please include brief affiliations for the people thanked in the Acknowledgements section.
Please provide a brief affiliation (University/Institute/Company/Organisation, town/city, state
[for USA, Canada, Australia] and country) for the person that assisted you in the
preparation/writing of the manuscript.
Please provide details of any compensation given to the person that assisted you in the
preparation/writing of the manuscript.
Funding
Please provide details of any funding used in this research. Where no specific funding was
received, please insert the following statement:
This research received no specific grant from any funding agency in the public, commercial
or not-for-profit sectors
Potential conflicts of interest related to project funding
The ICMJE uniform requirements for manuscripts submitted to medical journals state that
authors should describe the role of the study sponsor, if any, in study design; collection,
analysis, and interpretation of data; writing the report; and the decision to submit the report
for publication, e.g. ‘The sponsor provided editorial assistance only.’, ‘The sponsor was
involved in study design and data collection only’
If the supporting source had no such involvement, the authors should state ‘The study
sponsor was not involved in the design of the study; the collection, analysis, and
interpretation of data; writing the report; or the decision to submit the report for publication.’
Funding by UK research councils
From April 2013 all papers funded (in full or in part) by one of the UK’s Research Councils
(Biotechnology & Biological Sciences Research Council [BBSRC]; Economic & Social
Research Council [ESRC]; Engineering & Physical Sciences Research Council [EPSRC];
Medical Research Council [MRC]; Science & Technology Facilities Council [STFC] must
include details of the funding that supported the research and, if applicable, a statement on
how the underlying research materials such as data, samples or models can be accessed.
Please add funding details to the funding statement and access details under a new
subheading ‘Access to research materials’. Please note that the policy does not require that
the data must be made open. If there are compelling reasons to protect access to the data, e.g.
commercial confidentiality or legitimate sensitivities around data derived from potentially
identifiable human participants, these should be included in the statement.
Page 29 of 40
To comply with the RCUK’s open access policy, authors of papers to be published in
Diabetologia must select Springer’s Open Choice model of publication (emailed details of
how to do so will reach you after your paper has been copyedited). The journal will provide
immediate and unrestricted access to the publisher’s final version of the paper (the Version of
Record), and allow immediate deposition of the Version of Record in other repositories
without restriction on re-use. This will involve payment of an ‘Article Processing Charge’
(APC) to the publisher, Springer. The paper will be published under the Creative Commons
Attribution (CC BY) license, which lets others modify, build upon and/or distribute the
licensed work (including for commercial purposes) as long as the original author is credited.
Funding by the Wellcome Trust
To comply with the Wellcome Trust’s open access policy, authors of Wellcome-funded
papers to be published in Diabetologia must select Springer’s Open Choice model of
publication (emailed details of how to do so will reach you after your paper has been
copyedited). The journal will provide immediate and unrestricted access to the publisher’s
final version of the paper (the Version of Record), and allow immediate deposition of the
Version of Record in other repositories without restriction on re-use. This will involve
payment of an ‘Article Processing Charge’ (APC) to the publisher, Springer. The paper will
be published under the Creative Commons Attribution (CC BY) license, which lets others
modify, build upon and/or distribute the licensed work (including for commercial purposes)
as long as the original author is credited.
Contribution statement
The requirements of the International Committee of Medical Journal Editors state that
authorship credit should be based on:
(1) substantial contribution to conception and design, acquisition of data, or analysis and
interpretation of data;
(2) drafting the article or revising it critically for important intellectual content;
and
(3) final approval of the version to be published.
Each of these three conditions must be met by each author.
Your contribution statement has been checked, but it is not clear how XXX and XXX meet
condition #1 (conception and design, acquisition of data, or analysis and interpretation of
data), XXX and XXX meet condition #2 (drafting or revising the article), and XXX and XXX
have not approved the final version.
Please could you check your contribution statement and amend as necessary.
[To add if necessary]
Please identify in the contribution statement which author is responsible for the integrity of
the work as a whole.
Guarantor
Page 30 of 40
In accordance with the Recommendations for the Conduct, Reporting, Editing, and
Publication of Scholarly Work in Medical Journals (ICMJE Recommendations 2013;
http://www.icmje.org/recommendations/), Diabetologia now identifies who is responsible for
the integrity of the work as a whole. The guarantor accepts full responsibility for the work
and/or the conduct of the study, had access to the data, and controlled the decision to publish.
Please identify the author(s) who is guarantor of this paper by stating at the end of your
Contribution Statement e.g. 'XX is responsible for the integrity of the work as a whole' or
'XX is the guarantor of this
work'.
Page 31 of 40
Duality of interest
Please liaise with all co-authors and supply a duality of interest statement listing any current
or past (within the last 12 months) relationship with a company/organisation that could
benefit financially from the publication of the data in this manuscript. Please disclose any
competing interests and pertinent relationships of all authors with for-profit companies.
If there is no duality of interest please insert the following statement: ‘The authors declare
that there is no duality of interest associated with this manuscript.’
Data in public repositories
If data have been deposited in a public repository, please include details in a section ‘Access
to research materials’ at the end of the paper.
<Back to index>
Page 32 of 40
REFERENCES
Author name/reference mismatch
Reference no. [000] is not by XXX. Please advise.
Abstract out-of-date
Citations to abstracts are only permissible if the abstract was published in 2015 or 2014.
Please replace with details of a full published paper. If this is not possible, please cite as
‘unpublished results’ or ‘unpublished data’, listing all the authors and deleting this reference
(please remember to renumber the subsequent references in the text and in the list). For
authors that any are not listed as authors of the present paper, we require written consent to
cite their results. Please email a copy of this confirmation directly to us.
[Note that out-of-date abstracts are permissible in Systematic Reviews and Meta-Analyses.]
Reference in preparation/submitted
Reference to articles ‘in preparation’ or ‘submitted’ are not permitted. Please delete these
from the reference list and change text citations to ‘unpublished results’ or ‘personal
communication’ preceded by a list of contributors and their affiliations. Please note that we
require written consent to publication from the author of the communication. Please email a
copy of this confirmation directly to us.
<Back to index>
In press
You state that reference no. [000] is ‘in press’.
If possible, please provide details (volume number, page range) or the digital object identifier
(DOI) number. If the DOI is not yet available, we require written evidence that the paper has
been accepted. Please email a copy of this confirmation directly to us.
<Back to index>
Accepted for publication
Reference 000: Has this paper now been accepted for publication? If so, please provide
written confirmation of this from the journal concerned.
If the paper has not been accepted, the paper should be cited as 'unpublished results' in the
text (you will need to re-number subsequent references in the text and in the reference list).
Please insert the names of the authors of the unpublished results. For authors that are not
Page 33 of 40
listed as authors of the present paper, we require written consent to cite their results. Please
email a copy of this confirmation directly to us.
<Back to index>
ePub ahead of print
Please provide the DOI number, or the volume and page numbers if they are now available.
Websites
Please give the date that the site was accessed (day/month/year).
<Back to index>
Cochrane reviews
The reference to a Cochrane review has been amended in line with their recommendations
(see www.cochrane.org/index.htm).
Page 34 of 40
FIGURES
Figure part labelling
[Delete as appropriate]
Journal style does not allow reference to ‘left panel’, ‘right panel’, ‘upper panel’ or ‘lower
panel’. As the panels in the figure are clearly labelled, these terms have been deleted from the
legend.
To avoid reference to ‘left panel’, ‘right panel’, ‘upper panel’ or ‘lower panel’, in line with
journal style, Figure X has been relabelled [please add specific details].
Please change figure citations in the text to ensure that these new figure parts are correctly
cited, where appropriate.
Deletion of legend
The key has been deleted from the figure and the information added to the legend.
Deletion of p values
p values have been deleted from the figure and the information added to the legend.
<Back to index>
Figures not cited in rising order
Figures should be cited in rising order in the text (they appear in the order XXX). Please renumber or re-order figures as appropriate and amend citations in the text if necessary.
Explanation of statistical symbols
Please provide an explanation for the *, ** and *** symbols in the legend. Please note that
these symbols are reserved for *p<0.05, **p<0.01, ***p<0.001, respectively. Alternative
symbols can be used in the order †, ‡, §, ¶, if needed; # and $ signs should not be used.
Change of statistical symbols
Non-standard symbols to indicate significance have been replaced by standard symbols in the
legend and on the figure itself.
Standard statistical notation is *p<0.05, **p<0.01, ***p<0.001; usual order for symbols for
different comparisons is: *, †, ‡, §, ¶; # and $ signs should not be used.
Non-standard statistics (e.g. ***p<0.003)
Page 35 of 40
Standard statistical notation is *p<0.05, **p<0.01, ***p<0.001; the following symbols can be
used either for non-standard statistical levels or for different comparisons: *, †, ‡, §, ¶; # and
$ signs should not be used. Please either change the standard symbols to a single nonstandard symbol or change the p value to a standard one, e.g. ***p<0.003 could be changed
either to †p<0.003 or **p<0.01
p values
Please clarify which variables are being compared.
High resolution figures
Please supply high resolution versions of your figures:
Line graphs: EPS, AI or PowePoint vector files if possible, or otherwise TIFF files saved at
1200 dpi
Micrographs: TIFF files saved at 600 dpi
Composite figures (line graphs and micrographs): EPS, AI or PowePoint vector files if
possible, or otherwise TIFF files saved at 600 dpi
Forest plots
Please provide a new version of your forest plot (Fig. XXX) with the following amendments:
[Choose from list]
Please include ‘et al’ with the author name (or the second author name if there are only two
authors).
Please include the year for each study (optional)
Please include reference citation numbers shown in square brackets after the year of the study.
For example:
ADVANCE [23]
Smith et al (2008) [14]
Brown et al (2004) [3]
[List end]
Page 36 of 40
Scale bars
Please give details of magnifications of micrographs in the figure legends, or add scale bars
to the figures. If scale bars are added, please add the bar only, and give the size in the legend.
<Back to index>
Page 37 of 40
TABLES
Tables not cited in rising order
Tables should be cited in rising order in the text (they appear in the order XXX). Please renumber or re-order tables as appropriate and amend citations in the text if necessary.
Formatting (gridlines)
Please note that the typesetter will not print internal gridlines. Please make any amendments
necessary.
Formatting (bold)
Please note that the typesetter will not print bold in the table. Please make any amendments
necessary.
<Back to index>
Formatting (rows of space)
Please note that the typesetter will not print internal rows of space. Please amend as
necessary.
Formatting (bold type)
Please note that the typesetter will not print bold in the tables. Please amend as necessary,
using footnotes if needed.
Formatting changes
Some formatting changes have been made to the tables in line with journal style. Cell size
and font will be adjusted by the typesetters to ensure optimal presentation.
<Back to index>
Page 38 of 40
ESM
ESM files
Electronic supplementary material (ESM) will be published online as received without any
editorial changes. You are welcome to take this opportunity to revise your ESM in the light
of the copy-editor’s changes and queries to ensure that the ESM is consistent with the main
text. In particular, please check the following:
[Choose from list]
Gene symbol styling is appropriate for mouse/rat vs human and consistent with main text
Protein abbreviations are correctly styled and consistent with main text
SI units are used throughout (e.g. mmol/l for plasma glucose, pmol/l for plasma insulin, Bq
for radiation, etc.)
Abbreviations not used and defined in the main text are explained
[List end]
[Choose from list]
You may also wish to amend the titles of your ESM documents to be consistent with the
citations in the copy-edited text of your paper (e.g. ESM Fig. 1).
Please send any amended ESM documents as individual PDF files, using separate files for
ESM text (methods and results), lists of study group members (if applicable), individual
tables and individual figures.
Table headings and footnotes should be included above or below the table, in the same pdf.
ESM figure legends should be included in the same pdf as the accompanying ESM figure;
please do not supply the legends in a separate document.
ESM reference list: please note that each part of your ESM (ie, each individual table, each
individual figure, text etc.) is published separately online. Each part must therefore have its
own reference list. Please revise your ESM so that this is the case.
If your study included the use of a questionnaire that is not referenced and publicly available,
please include the questionnaire as ESM.
[List end]
<Back to index>
Page 39 of 40
COMMENTS (LETTERS)
Comment title
Please supply a unique title for your comment.
Reply to comment, title
Reply to comment: Please use the title of the comment on your paper as your title, followed
by the authors of the comment and ‘[letter]’. For example ‘ … . Reply to White CH, Brown P
[Substitute appropriate names] [letter]
<Back to index>
Page 40 of 40